Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025 - … against death in a robust ferret clade 2.3.4.4b challenge model, compared with 0% survival in placebo-treated animals. … against death in a robust ferret clade 2.3.4.4b challenge model, compared with 0% survival in placebo-treated animals. … against death in a robust ferret clade 2.3.4.4b challenge model, compared with 0% survival in placebo-treated animals. …
News

Vaxart CEO Issues Letter to Stockholders

August 8, 2025 - … showed 100% protection in a robust ferret challenge model. Full results will be published upon completion of our … showed 100% protection in a robust ferret challenge model. Full results will be published upon completion of our … showed 100% protection in a robust ferret challenge model. Full results will be published upon completion of our …
News

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

News

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025 - … candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals … against death in a robust ferret clade 2.3.4.4b challenge model, compared with 0% survival in placebo-treated animals. … candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals …
News

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

March 20, 2025 - … clinical trials, showed protection in a human challenge model, and elicited mucosal and systemic immunity in older … published data demonstrating protection in a preclinical model against avian influenza after oral immunization (Clin … clinical trials, showed protection in a human challenge model, and elicited mucosal and systemic immunity in older …
News

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

January 14, 2025 - … published data demonstrating protection in a preclinical model against avian influenza after oral immunization (Clin … published data demonstrating protection in a preclinical model against avian influenza after oral immunization (Clin … published data demonstrating protection in a preclinical model against avian influenza after oral immunization (Clin …
News

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

August 28, 2024 - … reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis - - … reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis - - … reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis - - …
News

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

News

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

News

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

August 8, 2022 - … study and, if successful, develop a human challenge model based on the omicron variant of SARS-CoV-2, with the … study and, if successful, develop a human challenge model based on the omicron variant of SARS-CoV-2, with the … study and, if successful, develop a human challenge model based on the omicron variant of SARS-CoV-2, with the …
Scroll to Top